Market Place
Sourcing Support
Lantern Pharma Doses First Patient in Japan for HARMONIC™ Trial
19 Nov 2024 //
BUSINESSWIRE
Lantern Pharma Reports Q3 2024 Financial Results & Updates
07 Nov 2024 //
BUSINESSWIRE
Starlight Names Inaugural Scientific Advisory Board Members
05 Nov 2024 //
BUSINESSWIRE
Lantern Pharma to Present at ThinkEquity Conference on October 30
23 Oct 2024 //
BUSINESSWIRE
Lantern Pharma & Participate Hosts Two Public Webinars In October
21 Oct 2024 //
BUSINESSWIRE
Lantern Pharma Receives Fast-Track Designation In Glioblastoma
15 Oct 2024 //
BUSINESSWIRE
Lantern Pharma Gets FDA Rare Pediatric Designations For LP-184
23 Sep 2024 //
BUSINESSWIRE
Lantern Pharma Reports Q2 2024 Results And Business Updates
08 Aug 2024 //
BUSINESSWIRE
Lantern Pharma Reports LP-184`s Synergy With Checkpoint Inhibitors
07 Aug 2024 //
BUSINESSWIRE
Lantern Pharma Reports 86% Benefit In NSCLC HARMONIC Trial
05 Aug 2024 //
BUSINESSWIRE
Lantern Pharma To Report Q2 2024 Results On August 8
01 Aug 2024 //
BUSINESSWIRE
Lantern Pharma Progresses Molecular Diagnostic For LP-184 Patient Selection
10 Jul 2024 //
BUSINESSWIRE
Lantern Pharma Receives Japanese Patent For Drug Candidate LP-284
12 Jun 2024 //
BUSINESSWIRE
Lantern Pharma Q1 2024 Financials, Business Highlights
09 May 2024 //
BUSINESSWIRE
Oregon, Lantern Launch AI Collaboration On Cancer Metabolism Drug
06 May 2024 //
BUSINESSWIRE
Lantern To Report Q1 2024 Results On May 9 At 4:30pm ET
02 May 2024 //
BUSINESSWIRE
Lantern`s "Webinar Wednesdays" on Oncology Drug Development
24 Apr 2024 //
BUSINESSWIRE
Lantern Expands Harmonic NSCLC Never-Smoker Trial To Japan, Taiwan
22 Apr 2024 //
BUSINESSWIRE
Lantern Harnessing AI and Machine Learning
16 Apr 2024 //
PHARMIWEB
How Lantern Pharma`s AI is Changing the Game
05 Apr 2024 //
PRESS RELEASE
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results
18 Mar 2024 //
BUSINESSWIRE
Lantern Announces Initial Patients Dosed in First-In-Human Trial for LP-284
15 Mar 2024 //
BUSINESSWIRE
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Financial Results
11 Mar 2024 //
PRESS RELEASE
Lantern To Participate in HCW 1st Annual Virtual Conference
05 Mar 2024 //
BUSINESSWIRE
Lantern Pharma`s A.I. Platform, RADR®, Surpasses 60 Billion Data Points
04 Mar 2024 //
BUSINESSWIRE
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers
15 Feb 2024 //
BUSINESSWIRE
Starlight Therapeutics Announces Dr. Marc Chamberlain as Chief Medical Officer
17 Jan 2024 //
BUSINESSWIRE
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284
30 Nov 2023 //
BUSINESSWIRE
Lantern Pharma Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
Lantern Pharma to Report Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Lantern to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
10 Oct 2023 //
BUSINESSWIRE
Lantern Pharma Announces Publication in Clinical Cancer Research
03 Oct 2023 //
BUSINESSWIRE
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184
25 Sep 2023 //
BUSINESSWIRE
Lantern Pharma Receives IND Clearance from FDA Phase 1 Initiation for LP-284
18 Sep 2023 //
BUSINESSWIRE
Lantern Pharma to Present Data the Anti-Tumor Potency of Drug Candidate LP-284
31 Aug 2023 //
BUSINESSWIRE
Lantern Expands AI Capabilities of RADR® Platform Immune Checkpoint Inhibitors
28 Aug 2023 //
BUSINESSWIRE
Lantern Pharma Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results
02 Aug 2023 //
BUSINESSWIRE
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
17 Jul 2023 //
BUSINESSWIRE
Oncotarget Publishes Data by Lantern , Supporting Clinical Advancement of LP-284
26 Jun 2023 //
BUSINESSWIRE
Lantern Receives FDA Clearance of IND Application for Drug Candidate LP-184
12 Jun 2023 //
BUSINESSWIRE
Lantern Pharma Leverages AI Platform, RADR®, to Develop ADCs
08 Jun 2023 //
BUSINESSWIRE
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference
17 May 2023 //
BUSINESSWIRE
Lantern Pharma Reports1Q 2023 FYR and Operational Highlights
09 May 2023 //
BUSINESSWIRE
Lantern Pharma Chooses Reprocell to Support Phase 2 Harmonic Trial
03 May 2023 //
BUSINESSWIRE
Lantern Pharma Selects REPROCELL USA to & Support for the pH 2 Harmonic™
03 May 2023 //
BUSINESSWIRE
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict
02 May 2023 //
BUSINESSWIRE
Lantern Pharma Receives Notice of Allowance for Drug Candidate LP-284
13 Apr 2023 //
BUSINESSWIRE
Lantern Announces First Patient Dosed in the Phase 2 Study, Harmonic for LP-300
28 Mar 2023 //
BUSINESSWIRE
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
21 Mar 2023 //
BUSINESSWIRE
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results
20 Mar 2023 //
BUSINESSWIRE
Lantern Pharma to Present at the AACR Annual Meeting
15 Mar 2023 //
BUSINESSWIRE
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Financial Results
13 Mar 2023 //
BUSINESSWIRE
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank
13 Mar 2023 //
BUSINESSWIRE
Lantern Pharma Announces New Data for LP-100 with PARP Inhibitors
09 Mar 2023 //
BUSINESSWIRE
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality
08 Mar 2023 //
BUSINESSWIRE
Lantern Pharma Announces Formation of Starlight Therapeutics for CNS
06 Mar 2023 //
BUSINESSWIRE
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Trials
02 Mar 2023 //
BUSINESSWIRE
Lantern Pharma, TTC Oncology Partner to Advance Breast Cancer Drug with AI
27 Feb 2023 //
CONTRACT PHARMA
Lantern Further Enhances Capabilities of its AI Drug Discovery Platform, RADR
15 Feb 2023 //
BUSINESSWIRE
